Associated tags: Thalassemia, Pharmaceutical industry, Patient, PDE9, Sickle cell disease, Therapy, Heart failure, Heart failure with preserved ejection fraction, COVID-19, Security (finance), SCD, HBF, Fetal hemoglobin, NFE2L2, Development, Inflammation, Hemoglobinopathy, VOC, Society
Locations: NEW YORK, BOSTON, UNITED STATES, MA, US, REDWOOD CITY, CA, NY, NEW YORK CITY, NORTH AMERICA, LOUISIANA
Retrieved on:
Thursday, October 29, 2020
ET to discuss its third quarter 2020 financial results and recent business highlights.
Key Points:
- ET to discuss its third quarter 2020 financial results and recent business highlights.
- A live webcast will be available under Events and Presentations in the Investors section of the company's website at imaratx.com.
- The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 7573255.
- A replay of the webcast will be archived on the Imara website following the presentation.
Dosing of the first patient in the Forte Phase 2b clinical trial marks an important milestone for Imara as we begin clinical evaluation of IMR-687 for the first time in patients with beta-thalassemia, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
Key Points:
- Dosing of the first patient in the Forte Phase 2b clinical trial marks an important milestone for Imara as we begin clinical evaluation of IMR-687 for the first time in patients with beta-thalassemia, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- Dr. Ballal continued, Patient dosing in the Forte 2b clinical trial follows initiation of dosing this August in our Ardent Phase 2b clinical trial in patients with sickle cell disease.
- These advancements transform Imara into a company with a drug candidate in multiple indications across global, multi-center clinical trials.
- The global, randomized, double-blind, placebo-controlled, multicenter Forte Phase 2b clinical trial will evaluate the safety and tolerability of IMR-687 in approximately 120 adult beta-thalassemia patients.
Retrieved on:
Wednesday, September 2, 2020
Branches of biology,
Medical specialties,
Clinical medicine,
Hemoglobins,
RTT,
Respiratory physiology,
Health in Africa,
Red blood cell,
Respiration,
Thalassemia,
Beta thalassemia,
Sickle cell disease Key Points:
- ET.
- Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin.
- Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.
- IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.
IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD.
Key Points:
- IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD.
- We are pleased to have received Orphan Drug designation from the European Commission, reinforcing the unmet need for more effective treatment options for patients with sickle cell disease, a rare blood disorder characterized by debilitating pain, progressive multi-organ damage and early death, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- We are making positive strides to advance IMR-687 for the treatment of sickle cell disease, including the recent initiation and patient dosing of our Phase 2b clinical trial for this patient population.
- Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.
Key Points:
- ET
BOSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business highlights.
- Research and Development Expenses: Research and development expenses were $7.9million for the second quarter of 2020, as compared to $4.4million for the second quarter of 2019.
- General and Administrative Expenses: General and administrative expenses were $2.4million for the second quarter of 2020, as compared to $1.2million for the second quarter of 2019.
- ET to discuss its second quarter 2020 financial results and other business updates.
Retrieved on:
Thursday, August 13, 2020
Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
Key Points:
- Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- Imara previously announced data from the second planned interim analysis of its ongoing Phase 2a clinical trial of IMR-687 in adult patients with SCD.
- Imara expects to report top-line data from this Phase 2a clinical trial in the fourth quarter of 2020.
- The global, randomized, double-blind, placebo-controlled, multicenter Ardent Phase 2b clinical trial will enroll approximately 99 adult patients with sickle cell disease (SCD).
ET to discuss its second quarter 2020 financial results and other business updates.
Key Points:
- ET to discuss its second quarter 2020 financial results and other business updates.
- A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at imaratx.com.
- The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635.
- A replay of the webcast will be archived on the Imara website following the presentation.
Health,
Orphan drugs,
Articles,
Life sciences,
RTT,
Breakthrough therapy,
Fast track,
Thalassemia,
Beta thalassemia,
Food and Drug Administration,
Sickle cell disease,
Betibeglogene autotemcel The FDA previously granted Orphan Drug designation for IMR-687 for the treatment of patients with beta-thalassemia and Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of patients with sickle cell disease.
Key Points:
- The FDA previously granted Orphan Drug designation for IMR-687 for the treatment of patients with beta-thalassemia and Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of patients with sickle cell disease.
- We are pleased to receive from the FDA both Fast Track designation and Rare Pediatric Disease designation for IMR-687.
- Fast Track designation helps us create the opportunity to potentially accelerate the development of IMR-687 in beta-thalassemia.
- Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process.
Membership in the Russell 2000Index, which remains in place for one year, is based on membership in the broad-market Russell 3000Index.
Key Points:
- Membership in the Russell 2000Index, which remains in place for one year, is based on membership in the broad-market Russell 3000Index.
- We are pleased to be added to the Russell 2000 Index following our successful IPO in March and the progress weve made in the months since, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- For more information on the Russell 2000Index and the Russell U.S. Indexes reconstitution, go to the Russell Reconstitution section on the FTSE Russell website .
- FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles.
The response to the program has been overwhelming, with 47 quality applications for funding from organizations across the United States.
Key Points:
- The response to the program has been overwhelming, with 47 quality applications for funding from organizations across the United States.
- We hope these grants will provide a measure of relief to community-based organizations doing vital work for patients and their families.
- Importantly, each grant committee consisted of external reviewers and decisions to fund applications were made independent of Imara senior leadership.
- Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin.
